Boehringer, China's ZBPBD See First Part Of Biopharma JV Open This Year
This article was originally published in PharmAsia News
Executive Summary
Boehringer Ingelheim's $81.4 million manufacturing joint venture with a China state-run drug company is expected to have its first phase operational by the end of this year.